CAMBRIDGE, MA, USA I March 11, 2025 I Biogen Inc. (Nasdaq: BIIB) – announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase ...
The stock's fall snapped a seven-day winning streak.
Zacks Investment Research on MSN4h
Ionis Out-Licenses Rights for Rare Blood Cancer Drug to OnoIonis Pharmaceuticals IONS signed a license agreement with Japan-based Ono Pharmaceutical. Per the terms, Ono has acquired ...
In Part A of the trial, subjects will be given nine intravenous infusions of either the drug or placebo over a six-month period.
A step-up in protectionist threats between Canada and the US prompted another negative session on Wall Street on Tuesday, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback